KUALA LUMPUR, Sept 9 (Bernama) -- George Clinical, a global clinical research organisation with an extensive presence throughout the Asia-Pacific region, expands its team in China with the addition of Helen Xu as Project Director and Cell Gene Therapy Head.
According to a statement, she will be based in Beijing and joins a rapidly growing team responsible for expanding clinical research activity in China with biopharmaceutical, medical device and diagnostic sponsors.
“I am sure Helen will make an incredibly valuable contribution to the growth and development of clinical research operations and cell gene therapy studies across China,” said country head and regional head project operations, China, Zhenfei Yin.
Dr Xu obtained her MD in clinical medicine from Peking University Health Center. She is a licensed physician specialised in central nervous system (CNS) and has worked in the hospital setting for four years.
She entered the pharmaceutical industry in 2007 starting as a clinical research associate (CRA) and has since accumulated 15 years of valuable clinical research experience in China.
“With a growing presence across the country, it is an honour to be part of global CRO able to bring further clinical research to China that can positively impact cancer care around the world,” Dr Xu said.
Before joining George Clinical, Dr Xu had served GSK, BI, Wuxiapp, a Chinese clinical research organisation, CASI, and Carsgen, a CAR-T biotech firm.
Her clinical trial experience covers the whole development lifecycle starting from phase I through PMS, the majority of the trial experiences being with pivotal trials.
Additional new team members will be joining the organisation to support the team in China with medical expertise.
-- BERNAMA
No comments:
Post a Comment